Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?
[Display omitted] S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) were formulated into in situ forming implants (ISI) and microparticles (ISM) using PLGA and either N-methyl-2-pyrrolidone (NMP) or triacetin. Physicochemical characterization was carried out, including the study...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmaceutics and biopharmaceutics 2013-11, Vol.85 (3), p.640-649 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 649 |
|---|---|
| container_issue | 3 |
| container_start_page | 640 |
| container_title | European journal of pharmaceutics and biopharmaceutics |
| container_volume | 85 |
| creator | Parent, Marianne Boudier, Ariane Dupuis, François Nouvel, Cécile Sapin, Anne Lartaud, Isabelle Six, Jean-Luc Leroy, Pierre Maincent, Philippe |
| description | [Display omitted]
S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) were formulated into in situ forming implants (ISI) and microparticles (ISM) using PLGA and either N-methyl-2-pyrrolidone (NMP) or triacetin. Physicochemical characterization was carried out, including the study of matrix structure and degradation. A strong correlation between drug hydrophobicity and the in vitro release profiles was observed: whatever the formulation, GSNO and SNAP were completely released after ca. 1day and 1week, respectively. Then, selected formulations (i.e., SNAP-loaded NMP formulations) demonstrated the ability to sustain the vasodilation effect of SNAP, as shown by monitoring the arterial pressure (telemetry) of Wistar rats after subcutaneous injection. Both ISI and ISM injections resulted in a 3-fold extended decrease in pulse arterial pressure compared with the unloaded drug, without significant decrease in the mean arterial pressure. Hence, the results emphasize the suitability of these formulations as drug delivery systems for S-nitrosothiols, widening their therapeutic potential. |
| doi_str_mv | 10.1016/j.ejpb.2013.08.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01273175v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641113002841</els_id><sourcerecordid>1462188692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-26845ef386c526ecbed8fc71033792f05180d1bbbbf4c8d02a7b7215e2d0e443</originalsourceid><addsrcrecordid>eNqFkV-L1DAUxYMo7uzqF_BB-qgPrTf_mhQEGRbXFQYU3PfQpjdMxk4zJunCfntTZ91HvRAuufzO4SaHkDcUGgq0_XBo8HAaGgaUN6AbAPmMbKhWvOZC0OdkAx3v6lZQekEuUzoAgFBSvyQXjHdSSNAb8n0bsfJzlXxeKhficZn67MOcqrzH6ic-pHX651JO7E-4ZG8rt-SlCIOrftSzzzGkkPc-TOnTK_LC9VPC14_9itzdfL67vq133758vd7uaisYzzVrtZDouG6tZC3aAUftrKLAueqYA0k1jHQo5YTVI7BeDYpRiWwEFIJfkfdn230_mVP0xz4-mNB7c7vdmXUGlClOlbynhX13Zk8x_FowZXP0yeI09TOGJRmqueKsVQz-j4qWUa3bjhWUnVFbXp8iuqc1KJg1H3Mwaz5mzceANiWfInr76L8MRxyfJH8DKcDHM4Dl7-49RpOsx9ni6CPabMbg_-X_G_CZn9w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1462188692</pqid></control><display><type>article</type><title>Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Parent, Marianne ; Boudier, Ariane ; Dupuis, François ; Nouvel, Cécile ; Sapin, Anne ; Lartaud, Isabelle ; Six, Jean-Luc ; Leroy, Pierre ; Maincent, Philippe</creator><creatorcontrib>Parent, Marianne ; Boudier, Ariane ; Dupuis, François ; Nouvel, Cécile ; Sapin, Anne ; Lartaud, Isabelle ; Six, Jean-Luc ; Leroy, Pierre ; Maincent, Philippe</creatorcontrib><description>[Display omitted]
S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) were formulated into in situ forming implants (ISI) and microparticles (ISM) using PLGA and either N-methyl-2-pyrrolidone (NMP) or triacetin. Physicochemical characterization was carried out, including the study of matrix structure and degradation. A strong correlation between drug hydrophobicity and the in vitro release profiles was observed: whatever the formulation, GSNO and SNAP were completely released after ca. 1day and 1week, respectively. Then, selected formulations (i.e., SNAP-loaded NMP formulations) demonstrated the ability to sustain the vasodilation effect of SNAP, as shown by monitoring the arterial pressure (telemetry) of Wistar rats after subcutaneous injection. Both ISI and ISM injections resulted in a 3-fold extended decrease in pulse arterial pressure compared with the unloaded drug, without significant decrease in the mean arterial pressure. Hence, the results emphasize the suitability of these formulations as drug delivery systems for S-nitrosothiols, widening their therapeutic potential.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2013.08.005</identifier><identifier>PMID: 23954508</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Arterial Pressure - drug effects ; Cardiology and cardiovascular system ; Chemistry, Pharmaceutical ; Delayed-Action Preparations ; Drug Carriers - chemistry ; Drug Delivery Systems ; Drug Implants ; Galenic pharmacology ; Human health and pathology ; Hydrophobic and Hydrophilic Interactions ; In situ implants ; In situ microparticles ; Lactic Acid - chemistry ; Life Sciences ; Male ; Medication ; Microspheres ; Nitric oxide donors ; Pharmaceutical sciences ; Pharmacology ; Polyglycolic Acid - chemistry ; Pulse arterial pressure ; Pyrrolidinones - chemistry ; Rats ; Rats, Wistar ; S-Nitroso-N-Acetylpenicillamine - administration & dosage ; S-Nitroso-N-Acetylpenicillamine - chemistry ; S-Nitrosoglutathione - administration & dosage ; S-Nitrosoglutathione - chemistry ; S-Nitrosoglutathione - pharmacology ; S-nitrosothiols ; Sustained release ; Telemetry ; Triacetin - chemistry ; Vasodilation - drug effects ; Vasodilator Agents - administration & dosage ; Vasodilator Agents - chemistry ; Vasodilator Agents - pharmacology</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2013-11, Vol.85 (3), p.640-649</ispartof><rights>2013 Elsevier B.V.</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-26845ef386c526ecbed8fc71033792f05180d1bbbbf4c8d02a7b7215e2d0e443</citedby><cites>FETCH-LOGICAL-c423t-26845ef386c526ecbed8fc71033792f05180d1bbbbf4c8d02a7b7215e2d0e443</cites><orcidid>0000-0002-4154-187X ; 0000-0002-7447-9806 ; 0000-0003-1151-6953 ; 0000-0001-5975-3646</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejpb.2013.08.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23954508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-01273175$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Parent, Marianne</creatorcontrib><creatorcontrib>Boudier, Ariane</creatorcontrib><creatorcontrib>Dupuis, François</creatorcontrib><creatorcontrib>Nouvel, Cécile</creatorcontrib><creatorcontrib>Sapin, Anne</creatorcontrib><creatorcontrib>Lartaud, Isabelle</creatorcontrib><creatorcontrib>Six, Jean-Luc</creatorcontrib><creatorcontrib>Leroy, Pierre</creatorcontrib><creatorcontrib>Maincent, Philippe</creatorcontrib><title>Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted]
S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) were formulated into in situ forming implants (ISI) and microparticles (ISM) using PLGA and either N-methyl-2-pyrrolidone (NMP) or triacetin. Physicochemical characterization was carried out, including the study of matrix structure and degradation. A strong correlation between drug hydrophobicity and the in vitro release profiles was observed: whatever the formulation, GSNO and SNAP were completely released after ca. 1day and 1week, respectively. Then, selected formulations (i.e., SNAP-loaded NMP formulations) demonstrated the ability to sustain the vasodilation effect of SNAP, as shown by monitoring the arterial pressure (telemetry) of Wistar rats after subcutaneous injection. Both ISI and ISM injections resulted in a 3-fold extended decrease in pulse arterial pressure compared with the unloaded drug, without significant decrease in the mean arterial pressure. Hence, the results emphasize the suitability of these formulations as drug delivery systems for S-nitrosothiols, widening their therapeutic potential.</description><subject>Animals</subject><subject>Arterial Pressure - drug effects</subject><subject>Cardiology and cardiovascular system</subject><subject>Chemistry, Pharmaceutical</subject><subject>Delayed-Action Preparations</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Drug Implants</subject><subject>Galenic pharmacology</subject><subject>Human health and pathology</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>In situ implants</subject><subject>In situ microparticles</subject><subject>Lactic Acid - chemistry</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medication</subject><subject>Microspheres</subject><subject>Nitric oxide donors</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology</subject><subject>Polyglycolic Acid - chemistry</subject><subject>Pulse arterial pressure</subject><subject>Pyrrolidinones - chemistry</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>S-Nitroso-N-Acetylpenicillamine - administration & dosage</subject><subject>S-Nitroso-N-Acetylpenicillamine - chemistry</subject><subject>S-Nitrosoglutathione - administration & dosage</subject><subject>S-Nitrosoglutathione - chemistry</subject><subject>S-Nitrosoglutathione - pharmacology</subject><subject>S-nitrosothiols</subject><subject>Sustained release</subject><subject>Telemetry</subject><subject>Triacetin - chemistry</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - administration & dosage</subject><subject>Vasodilator Agents - chemistry</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV-L1DAUxYMo7uzqF_BB-qgPrTf_mhQEGRbXFQYU3PfQpjdMxk4zJunCfntTZ91HvRAuufzO4SaHkDcUGgq0_XBo8HAaGgaUN6AbAPmMbKhWvOZC0OdkAx3v6lZQekEuUzoAgFBSvyQXjHdSSNAb8n0bsfJzlXxeKhficZn67MOcqrzH6ic-pHX651JO7E-4ZG8rt-SlCIOrftSzzzGkkPc-TOnTK_LC9VPC14_9itzdfL67vq133758vd7uaisYzzVrtZDouG6tZC3aAUftrKLAueqYA0k1jHQo5YTVI7BeDYpRiWwEFIJfkfdn230_mVP0xz4-mNB7c7vdmXUGlClOlbynhX13Zk8x_FowZXP0yeI09TOGJRmqueKsVQz-j4qWUa3bjhWUnVFbXp8iuqc1KJg1H3Mwaz5mzceANiWfInr76L8MRxyfJH8DKcDHM4Dl7-49RpOsx9ni6CPabMbg_-X_G_CZn9w</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Parent, Marianne</creator><creator>Boudier, Ariane</creator><creator>Dupuis, François</creator><creator>Nouvel, Cécile</creator><creator>Sapin, Anne</creator><creator>Lartaud, Isabelle</creator><creator>Six, Jean-Luc</creator><creator>Leroy, Pierre</creator><creator>Maincent, Philippe</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-4154-187X</orcidid><orcidid>https://orcid.org/0000-0002-7447-9806</orcidid><orcidid>https://orcid.org/0000-0003-1151-6953</orcidid><orcidid>https://orcid.org/0000-0001-5975-3646</orcidid></search><sort><creationdate>20131101</creationdate><title>Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?</title><author>Parent, Marianne ; Boudier, Ariane ; Dupuis, François ; Nouvel, Cécile ; Sapin, Anne ; Lartaud, Isabelle ; Six, Jean-Luc ; Leroy, Pierre ; Maincent, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-26845ef386c526ecbed8fc71033792f05180d1bbbbf4c8d02a7b7215e2d0e443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Arterial Pressure - drug effects</topic><topic>Cardiology and cardiovascular system</topic><topic>Chemistry, Pharmaceutical</topic><topic>Delayed-Action Preparations</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Drug Implants</topic><topic>Galenic pharmacology</topic><topic>Human health and pathology</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>In situ implants</topic><topic>In situ microparticles</topic><topic>Lactic Acid - chemistry</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medication</topic><topic>Microspheres</topic><topic>Nitric oxide donors</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology</topic><topic>Polyglycolic Acid - chemistry</topic><topic>Pulse arterial pressure</topic><topic>Pyrrolidinones - chemistry</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>S-Nitroso-N-Acetylpenicillamine - administration & dosage</topic><topic>S-Nitroso-N-Acetylpenicillamine - chemistry</topic><topic>S-Nitrosoglutathione - administration & dosage</topic><topic>S-Nitrosoglutathione - chemistry</topic><topic>S-Nitrosoglutathione - pharmacology</topic><topic>S-nitrosothiols</topic><topic>Sustained release</topic><topic>Telemetry</topic><topic>Triacetin - chemistry</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - administration & dosage</topic><topic>Vasodilator Agents - chemistry</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parent, Marianne</creatorcontrib><creatorcontrib>Boudier, Ariane</creatorcontrib><creatorcontrib>Dupuis, François</creatorcontrib><creatorcontrib>Nouvel, Cécile</creatorcontrib><creatorcontrib>Sapin, Anne</creatorcontrib><creatorcontrib>Lartaud, Isabelle</creatorcontrib><creatorcontrib>Six, Jean-Luc</creatorcontrib><creatorcontrib>Leroy, Pierre</creatorcontrib><creatorcontrib>Maincent, Philippe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parent, Marianne</au><au>Boudier, Ariane</au><au>Dupuis, François</au><au>Nouvel, Cécile</au><au>Sapin, Anne</au><au>Lartaud, Isabelle</au><au>Six, Jean-Luc</au><au>Leroy, Pierre</au><au>Maincent, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>85</volume><issue>3</issue><spage>640</spage><epage>649</epage><pages>640-649</pages><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted]
S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) were formulated into in situ forming implants (ISI) and microparticles (ISM) using PLGA and either N-methyl-2-pyrrolidone (NMP) or triacetin. Physicochemical characterization was carried out, including the study of matrix structure and degradation. A strong correlation between drug hydrophobicity and the in vitro release profiles was observed: whatever the formulation, GSNO and SNAP were completely released after ca. 1day and 1week, respectively. Then, selected formulations (i.e., SNAP-loaded NMP formulations) demonstrated the ability to sustain the vasodilation effect of SNAP, as shown by monitoring the arterial pressure (telemetry) of Wistar rats after subcutaneous injection. Both ISI and ISM injections resulted in a 3-fold extended decrease in pulse arterial pressure compared with the unloaded drug, without significant decrease in the mean arterial pressure. Hence, the results emphasize the suitability of these formulations as drug delivery systems for S-nitrosothiols, widening their therapeutic potential.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23954508</pmid><doi>10.1016/j.ejpb.2013.08.005</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4154-187X</orcidid><orcidid>https://orcid.org/0000-0002-7447-9806</orcidid><orcidid>https://orcid.org/0000-0003-1151-6953</orcidid><orcidid>https://orcid.org/0000-0001-5975-3646</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-6411 |
| ispartof | European journal of pharmaceutics and biopharmaceutics, 2013-11, Vol.85 (3), p.640-649 |
| issn | 0939-6411 1873-3441 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01273175v1 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Arterial Pressure - drug effects Cardiology and cardiovascular system Chemistry, Pharmaceutical Delayed-Action Preparations Drug Carriers - chemistry Drug Delivery Systems Drug Implants Galenic pharmacology Human health and pathology Hydrophobic and Hydrophilic Interactions In situ implants In situ microparticles Lactic Acid - chemistry Life Sciences Male Medication Microspheres Nitric oxide donors Pharmaceutical sciences Pharmacology Polyglycolic Acid - chemistry Pulse arterial pressure Pyrrolidinones - chemistry Rats Rats, Wistar S-Nitroso-N-Acetylpenicillamine - administration & dosage S-Nitroso-N-Acetylpenicillamine - chemistry S-Nitrosoglutathione - administration & dosage S-Nitrosoglutathione - chemistry S-Nitrosoglutathione - pharmacology S-nitrosothiols Sustained release Telemetry Triacetin - chemistry Vasodilation - drug effects Vasodilator Agents - administration & dosage Vasodilator Agents - chemistry Vasodilator Agents - pharmacology |
| title | Are in situ formulations the keys for the therapeutic future of S-nitrosothiols? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A43%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20in%20situ%20formulations%20the%20keys%20for%20the%20therapeutic%20future%20of%20S-nitrosothiols?&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Parent,%20Marianne&rft.date=2013-11-01&rft.volume=85&rft.issue=3&rft.spage=640&rft.epage=649&rft.pages=640-649&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2013.08.005&rft_dat=%3Cproquest_hal_p%3E1462188692%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1462188692&rft_id=info:pmid/23954508&rft_els_id=S0939641113002841&rfr_iscdi=true |